New drug aims to tame dangerous blood fats in heart patients

NCT ID NCT06797401

Recruiting now Disease control Sponsor: Ribocure Pharmaceuticals AB Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called RBD5044 in 120 adults with mixed dyslipidemia, a condition where both cholesterol and triglycerides are high. Participants receive either the drug or a placebo twice over 12 months to see if it safely lowers triglyceride levels. The goal is to better control blood fats and reduce heart disease risk.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias hyperlipidemia inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDEMIAS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Akademiska Sjukhuset Uppsala
RECRUITING

Uppsala, Sweden

Contact
AkardoMedSite
RECRUITING

Stockholm, Sweden

Contact
Lunds Universitetssjukhus
RECRUITING

Lund, Sweden

Contact
Ribocure Clinic/Ribocure Pharmaceuticals AB
RECRUITING

Mölndal, Sweden

Contact